Antibody–drug conjugate - Wikipedia
WEBAntibody–drug conjugates or ADCs are a class of biopharmaceutical drugs designed as a targeted therapy for treating cancer. [1] Unlike chemotherapy, ADCs are intended to target and kill tumor cells while sparing healthy cells. As of 2019, some 56 pharmaceutical companies were developing ADCs.
Introduction to Antibody-Drug Conjugates - PMC - National …
WEBOct 27, 2021 · Antibody-drug conjugates (ADCs) are innovative biopharmaceutical products in which a monoclonal antibody is linked to a small molecule drug with a stable linker. Most of the ADCs developed so far are for treating cancer, but there is enormous potential for using ADCs to treat other diseases.
A rationally designed ICAM1 antibody drug conjugate ... - Science
WEBMay 5, 2023 · An ICAM1 antibody conjugated with monomethyl auristatin E (MMAE) via a protease-cleavable valine-citrulline linker was identified as the optimal ADC formulation owing to its outstanding efficacy and safety, representing an effective ADC …
Antibody–Drug Conjugates—A Tutorial Review - PMC
WEBMay 15, 2021 · Antibody–drug conjugates (ADCs) are a family of targeted therapeutic agents for the treatment of cancer. ADC development is a rapidly expanding field of research, with over 80 ADCs currently in clinical development and eleven ADCs (nine containing small-molecule payloads and two with biological toxins) approved for use by …
The Evolving Landscape of Antibody–Drug Conjugates: In Depth …
WEBOct 11, 2023 · Here we provide a detailed overview of the recent advances in ADC research and consider future directions and challenges in promoting this promising platform to widespread therapeutic use.
Clinical translation of antibody drug conjugate dosing in ... - Science
WEBMay 31, 2024 · Antibody drug conjugates (ADCs) represent a rapidly growing class of therapeutics that includes six Food and Drug Administration (FDA)–approved agents for the treatment of patients with solid tumors.
Rise of Antibody-Drug Conjugates: The Present and Future
WEBMay 25, 2023 · Antibody-drug conjugates (ADCs) embody a simple, but elegant, vision for cancer therapy—the delivery of a potent cytotoxic agent to tumor cells with minimal damage to normal cells—so-called smart chemo.
Antibody-Drug Conjugates-A Tutorial Review - PubMed
WEBMay 15, 2021 · To this end, this tutorial review aims to serve as a reference material for ADCs and give readers a comprehensive understanding of ADCs; it explores and explains each ADC component (monoclonal antibody, linker moiety and cytotoxic payload) individually, highlights several EMA- and FDA-approved ADCs by …
Cancer-targeting antibody–drug conjugates drive dealmaking …
WEBFeb 26, 2024 · Antibody–drug conjugates (ADCs) are driving a multi-billion-dollar dealmaking frenzy. Big pharma is snapping up ADC assets and technologies amid accelerating approvals, broadening indications...
Antibody-Drug Conjugate-Based Therapeutics: State of the Science
WEBMar 11, 2019 · Antibody-drug conjugates (ADCs) are complex engineered therapeutics consisting of monoclonal antibodies, directed toward tumor-associated antigens, to which highly potent cytotoxic agents are attached using chemical linkers.